Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Heat Biologics, Inc.
Type
Public
Traded as NASDAQ: HTBX
Industry Biotechnology
Founded 2008
Headquarters Durham, NC
Key people
Jeffrey Wolf
(Chairman and Chief Executive Officer)
Products HS-110, HS-X20
Website www.heatbio.com

Heat Biologics Inc. is a US biotechnology company focused on the field of cancer immunotherapy. This company’s cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. ImPACT is in Phase II in NSCLC and bladder cancer.

ImPACT is a proposed cancer vaccine based on live, genetically-modified, irradiated human cells which secrete a broad spectrum of cancer-associated antigens as well as an immune adjuvant called gp96. Potential advantages of this product are use as an 'allogeneic', that is, 'off-the-shelf' immunotherapy, and its appplicability to a wide range of cancers. It is in phase II trials.

ImPACT originated in the late 1990s in work done at the University of Miami which showed that gp96, a heat shock protein resident in the endoplasmic reticulum could be made immunogenic if part of gp96 was replaced with the Fc portion of an IgG1 antibody to engineer a secretory form of gp96. In vivo gp96-Ig generated a strong CD8+ T cell response

ComPACT is a combination of a pan-antigen T cell priming vaccine and a T cell co-stimulator.

HS-410, also called vesigenurtacel-L, is currently in Phase II in Non-Muscle-Invasive Bladder Cancer (NMIBC), in combination with BCG. In Feb 2016 patient enrollment was paused (for lack of BCG).

HS 110, called viagenpumatucel-L, is in Phase II in NSCLC, in combination with cyclophosphamide. Another Phase I study is combining HS 110 with nivolumab and other checkpoint inhibitors.

Heat Biologics stock is traded on Nasdaq under the code HTBX. The company did its IPO on Nasdaq in mid-2013, with its stock commencing trading on 24 July 2013.

Heat Biologics' Chairman and CEO is Jeffrey Wolf, a serial Life Sciences entrepreneur who founded the company in 2008. Its Chief Scientific Officer is Dr. Jeff Hutchins.

Heat Biologics is headquartered in Durham, NC. Its office at 801 Capitola Drive is located near the I-40 about three miles to the southwest of Research Triangle Park and eight miles to the west of Raleigh–Durham International Airport.

Investment goal date:
Dividends reinvested
Heat Biologics, Inc. HTBX report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-08
--
--
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-14
-0.0900
-0.0900
Q1 2017
2017-05-11
-0.1200
-0.1200
Q4 2016
2017-03-31
-0.1200
-0.1400
Q3 2016
2016-11-10
-0.0800
-0.0800
Q2 2016
2016-08-15
-0.1700
-0.1700
Q1 2016
2016-05-11
-0.5000
-0.5000
Q4 2015
2016-02-18
-0.7800
-0.7700
Q3 2015
2015-10-30
-0.6200
-0.6200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
KHARITONOV MICHAEL
14.7000% (949960)
HTBX /
MONAHAN JOHN J
0.0800% (5169)
HTBX / ITUS /
Wolf Jeffrey Alan
11.0800% (716195)
HTBX / SYN /
BRIGHTLINE CAPITAL MANAGEMENT, LLC
10.7900% (697303)
HTBX /
Smith Edward B III
15.9800% (1033046)
HTBX /
Rosar Ann A
0.9800% (63236)
DARA / HTBX /
Belsky Paul
0.7300% (47190)
HTBX /
% ()